Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1

被引:7
|
作者
Mur, Pilar [1 ,2 ,3 ,4 ]
Viana-Errasti, Julen [1 ,2 ]
Garcia-Mulero, Sandra [4 ,5 ]
Magraner-Pardo, Lorena [6 ,7 ]
Munoz, Ines G. [8 ]
Pons, Tirso [9 ]
Capella, Gabriel [1 ,2 ,3 ]
Pineda, Marta [1 ,2 ,3 ]
Feliubadalo, Lidia [1 ,2 ,3 ]
Valle, Laura [1 ,2 ,3 ]
机构
[1] Catalan Inst Oncol, IDIBELL, Hereditary Canc Program, Barcelona, Spain
[2] IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Barcelona, Spain
[3] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[4] Catalan Canc Plan, Dept Hlth Catalonia, Barcelona, Spain
[5] Catalan Inst Oncol, Oncol Data Analyt Program ODAP, Unit Biomarkers & Susceptibil, Barcelona, Spain
[6] Inst Canc Res ICR, CRUK Gene Funct Lab, London, England
[7] Inst Canc Res ICR, Breast Canc Now Toby Robins Res Ctr, London, England
[8] Spanish Natl Canc Res Ctr CNIO, Struct Biol Program, Prot Crystallog Unit, Madrid, Spain
[9] Spanish Natl Res Council, Natl Ctr Biotechnol CNB CSIC, Dept Immunol & Oncol, Madrid, Spain
关键词
Polymerase proofreading-associated polyposis; PPAP; Polymerase epsilon; Polymerase delta; Proofreading deficiency; Mutational signatures; Variant classification; Hereditary cancer; DNA-POLYMERASE EPSILON; MICROSATELLITE INSTABILITY; MUTATIONS; CRITERIA; COLON; PATHOGENICITY; GUIDELINES; SIGNATURES; BLOCKADE; FEATURES;
D O I
10.1186/s13073-023-01234-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
BackgroundGermline variants affecting the proofreading activity of polymerases epsilon and delta cause a hereditary cancer and adenomatous polyposis syndrome characterized by tumors with a high mutational burden and a specific mutational spectrum. In addition to the implementation of multiple pieces of evidence for the classification of gene variants, POLE and POLD1 variant classification is particularly challenging given that non-disruptive variants affecting the proofreading activity of the corresponding polymerase are the ones associated with cancer. In response to an evident need in the field, we have developed gene-specific variant classification recommendations, based on the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) criteria, for the assessment of non-disruptive variants located in the sequence coding for the exonuclease domain of the polymerases.MethodsA training set of 23 variants considered pathogenic or benign was used to define the usability and strength of the ACMG/AMP criteria. Population frequencies, computational predictions, co-segregation data, phenotypic and tumor data, and functional results, among other features, were considered.ResultsGene-specific variant classification recommendations for non-disruptive variants located in the exonuclease domain of POLE and POLD1 were defined. The resulting recommendations were applied to 128 exonuclease domain variants reported in the literature and/or public databases. A total of 17 variants were classified as pathogenic or likely pathogenic, and 17 as benign or likely benign.ConclusionsOur recommendations, with room for improvement in the coming years as more information become available on carrier families, tumor molecular characteristics and functional assays, are intended to serve the clinical and scientific communities and help improve diagnostic performance, avoiding variant misclassifications.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Mononucleotide microsatellites destabilized by a POLD1 Exo domain mutation
    Oda, Shinya
    Shioi, Seijiro
    Takiguchi, Soichi
    Hidaka, Kyoko
    Fujikane, Ryosuke
    Hidaka, Masumi
    Nakatsu, Yoshimichi
    CANCER SCIENCE, 2022, 113 : 356 - 356
  • [32] Comprehensive analysis of POLE and POLD1 mutation in 9322 Chinese cancer patients
    Dong, Hua
    Bai, Yuezong
    Cao, Xinkai
    Wang, Yanyan
    Shi, Lin
    Li, Fugen
    Ye, Yizhou
    Sun, Shuyang
    CANCER RESEARCH, 2019, 79 (13)
  • [33] The landscape of POLE/POLD1 mutations in Chinese solid tumor patients.
    Pang, Linrong
    Xu, Tao
    Tao, Hua
    Chen, Gang
    Ni, Bin
    Zeng, Daobing
    Wang, Aodi
    Shi, Weiwei
    Wang, Kai
    Yao, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] POLE, POLD1 and RNF43 screening in serrated polyposis syndrome
    Soares de Lima, Y.
    Arnau-Collell, C.
    Diaz-Gay, M.
    Munoz, J.
    Carballal, S.
    Bonjoch, L.
    Moreira, L.
    Lozano, J.
    Ocana, T.
    Cuatrecasas, M.
    Diaz de Bustamante, A.
    Castells, A.
    Bujanda, L.
    Cubiella, J.
    Rodriguez-Alcalde, D.
    Balaguer, F.
    Ruiz-Ponte, C.
    Valle, L.
    Moreno, V.
    Castellvi-Bel, S.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 551 - 552
  • [35] Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma
    Zhu, Mingyu
    Cui, Haiyan
    Zhang, Lu
    Zhao, Kuo
    Jia, Xiaochen
    Jin, Hao
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (01) : 193 - 205
  • [36] Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas (vol 45, pg 136, 2013)
    Palles, Claire
    Cazier, Jean-Baptiste
    Howarth, Kimberley M.
    Domingo, Enric
    Jones, Angela M.
    Broderick, Peter
    Kemp, Zoe
    Spain, Sarah L.
    Almeida, Estrella Guarino
    Salguero, Israel
    Sherborne, Amy
    Chubb, Daniel
    Carvajal-Carmona, Luis G.
    Ma, Yusanne
    Kaur, Kulvinder
    Dobbins, Sara
    Barclay, Ella
    Gorman, Maggie
    Martin, Lynn
    Kovac, Michal B.
    Humphray, Sean
    Lucassen, Anneke
    Holmes, Christopher C.
    Bentley, David
    Donnelly, Peter
    Taylor, Jenny
    Petridis, Christos
    Roylance, Rebecca
    Sawyer, Elinor J.
    Kerr, David J.
    Clark, Susan
    Grimes, Jonathan
    Kearsey, Stephen E.
    Thomas, Huw J. W.
    McVean, Gilean
    Houlston, Richard S.
    Tomlinson, Ian
    NATURE GENETICS, 2013, 45 (06) : 713 - 713
  • [37] Unraveling the impact of a germline heterozygous POLD1 frameshift variant in serrated polyposis syndrome
    Bonjoch, Laia
    Soares de Lima, Yasmin
    Diaz-Gay, Marcos
    Dotti, Isabella
    Munoz, Jenifer
    Moreira, Leticia
    Carballal, Sabela
    Ocana, Teresa
    Cuatrecasas, Miriam
    Ortiz, Oswaldo
    Castells, Antoni
    Pellise, Maria
    Balaguer, Francesc
    Salas, Azucena
    Alexandrov, Ludmil B. B.
    Castellvi-Bel, Sergi
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [38] Race, Prevalence of POLE and POLD1 Mutations, and Survival Among Patients With Endometrial Cancer
    Zheng, Shuhua
    Donnelly, Eric D.
    Strauss, Jonathan B.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1058 - S1060
  • [39] POLE and POLD1 Variant Detection: Potential Immune-Checkpoint Inhibitor Biomarker
    Besharati, Sepideh
    Fazlollahi, Ladan
    Remotti, Helen
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 491 - 491
  • [40] POLE and POLD1 Variant Detection: Potential Immune-Checkpoint Inhibitor Biomarker
    Besharati, Sepideh
    Fazlollahi, Ladan
    Remotti, Helen
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 491 - 491